R43AI167567
Project Grant
Overview
Grant Description
HelioQuant: A platform for fast, label-free, automated evaluation of bioburden.
Awardee
Funding Goals
TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS, TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Texas
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 06/30/23 to 06/30/24 and the total obligations have decreased 3% from $233,475 to $227,471.
Heliowave Technologies was awarded
Project Grant R43AI167567
worth $227,471
from the National Institute of Allergy and Infectious Diseases in July 2022 with work to be completed primarily in Texas United States.
The grant
has a duration of 2 years and
was awarded through assistance program 93.855 Allergy and Infectious Diseases Research.
The Project Grant was awarded through grant opportunity PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed).
SBIR Details
Research Type
SBIR Phase I
Title
HelioQUANT: A Platform for Fast, Label-Free, Automated Evaluation of Bioburden
Abstract
Abstract Bioburden constitutes a key component of environmental monitoring programs in biomanufacturing facilities, where routine testing allows manufacturers to assess the efficiency of the cleaning and decontamination of pack- aging, product components, and worksurfaces. HelioWave Technologies, LLC, is dedicated to revolutionizing bioburden testing by developing products that dramatically increase the speed, efficiency, and usability, while lowering the cost of bioburden testing for materials and products used in the biomedical industry. The underlying approach used for bioburden testing—the assessment of microbial growth on solid media-- has remained un- changed for a century. HelioWave Technologies, LLC, is developing HelioQUANTTM, a novel bioburden testing technology platform that will replace outdated methods by combining advances in two broad technological areas, droplet microfluidics and impedance detection, to deliver a compelling bioburden testing solution. Droplet micro- fluidics systems use pico-liter-volume water-in-oil emulsion droplets that function as cell-encapsulated bioreac- tors for the performance of low cost, rapid, single-cell-resolution biological assays. Impedance spectroscopy- based cell detection is label-free, can detect broad ranges of microorganisms, at high speed. Over the past decade, the company’s academic partners have substantially advanced the basic science and engineering that supports the development of a system that integrates innovations in droplet microfluidics and impedance micros- copy for bioburden testing. The proposed HelioQUANTTM system, which leverages this expertise and innova- tions, will deliver dramatic reductions in cost and testing times, respectively, for bioburden evaluation. With these ideas in mind, the overarching technical objective of this proposal is to prototype the HelioQUANTTM bioburden testing platform. To achieve this goal, two Specific Aims will be pursued: (1). To advance the development of the droplet microfluidic module (HQ-DMMTM) of the HelioQUANTTM system; (2) To advance the development of the impedance detection module (HQ-IDMTM) of the HelioQUANTTM system. The outcome of the proposed work will be the development of the HelioQUANTTM prototype for bioburden assessment. The proposed work will also identify technical strengths and limitations (if any) of the proposed integrated system, and thereby set the stage for developing a “manufacture ready†integrated HelioQUANTTM product in Phase II of the NIH SBIR program.
Topic Code
NIAID
Solicitation Number
PA21-259
Status
(Complete)
Last Modified 2/20/25
Period of Performance
7/8/22
Start Date
6/30/24
End Date
Funding Split
$227.5K
Federal Obligation
$0.0
Non-Federal Obligation
$227.5K
Total Obligated
Activity Timeline
Transaction History
Modifications to R43AI167567
Additional Detail
Award ID FAIN
R43AI167567
SAI Number
R43AI167567-377513539
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Small Business
Awarding Office
75NM00 NIH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Funding Office
75NM00 NIH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Awardee UEI
F9T3KRMMEXM4
Awardee CAGE
8U1J5
Performance District
TX-90
Senators
John Cornyn
Ted Cruz
Ted Cruz
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases, National Institutes of Health, Health and Human Services (075-0885) | Health research and training | Grants, subsidies, and contributions (41.0) | $233,475 | 100% |
Modified: 2/20/25